Misplaced Pages

Umeclidinium bromide/vilanterol

Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromide	Muscarinic antagonist
Vilanterol	Ultra-long-acting β2 agonist
Clinical data
Trade names	Anoro Ellipta, others
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Anoro
Pregnancy category	AU: B3
Routes of administration	Inhalation
ATC code	R03AL03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only EU: Rx-only
Identifiers
CAS Number	2446159-58-4
KEGG	D10533

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD). It is administered by inhalation.

The most common side effects include upper respiratory tract infections, urinary tract infections, pharyngitis, sinusitis, nasopharyngitis, headache, cough, oropharyngeal pain, constipation and dry mouth.

In 2022, it was the 211th most commonly prescribed medication in the United States, with more than 1 million prescriptions.

References

1. "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
2. "Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Retrieved 29 October 2020.
3. "Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 24 November 2024.
4. ^ "Anoro Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
5. Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
6. "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. 18 December 2013.
7. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
8. "Umeclidinium; Vilanterol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

• Medicine

• Beta-adrenergic agonists
• Drugs acting on the respiratory system
• Long-acting beta2-adrenergic agonists
• Combination COPD drugs
• Muscarinic antagonists
• Drugs developed by GSK plc